1. Home
  2. APAM vs TRVI Comparison

APAM vs TRVI Comparison

Compare APAM & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Artisan Partners Asset Management Inc.

APAM

Artisan Partners Asset Management Inc.

HOLD

Current Price

$39.34

Market Cap

2.5B

Sector

Finance

ML Signal

HOLD

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

HOLD

Current Price

$17.37

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APAM
TRVI
Founded
1994
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.6B
IPO Year
2011
2019

Fundamental Metrics

Financial Performance
Metric
APAM
TRVI
Price
$39.34
$17.37
Analyst Decision
Hold
Strong Buy
Analyst Count
5
11
Target Price
$43.00
$21.55
AVG Volume (30 Days)
930.0K
3.0M
Earning Date
04-28-2026
05-05-2026
Dividend Yield
10.81%
N/A
EPS Growth
10.66
31.91
EPS
0.76
N/A
Revenue
$1,196,688,000.00
N/A
Revenue This Year
$5.96
N/A
Revenue Next Year
$5.05
N/A
P/E Ratio
$50.68
N/A
Revenue Growth
7.63
N/A
52 Week Low
$33.96
$6.55
52 Week High
$48.46
$20.22

Technical Indicators

Market Signals
Indicator
APAM
TRVI
Relative Strength Index (RSI) 64.04 50.62
Support Level $34.59 $10.07
Resistance Level $40.50 $20.19
Average True Range (ATR) 0.94 1.40
MACD 0.24 -0.23
Stochastic Oscillator 77.65 27.89

Price Performance

Historical Comparison
APAM
TRVI

About APAM Artisan Partners Asset Management Inc.

Artisan Partners Asset Management Inc is a investment management firm providing a range of investment strategies to a diverse group of clients around the world. Each of the company's strategies is managed by one of its several investment teams. Investment management services are offered to institutions through separate accounts and mutual funds. Artisan's investment offerings include several long-only, equity investment strategies across a multitude of market capitalization segments and investing styles in both the United States and international markets. The company operates as one segment in the investment management business. The company generates maximum portion of its revenues from clients domiciled in countries outside the United States.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: